DOI:
https://doi.org/10.7439/ijbr.v8i2.3926
Abstract
Hypertension is one of the most prevalent diseases of the world and is an unequivocal risk factor for cardiovascular morbidity and mortality. Hypertension is known to be associated with oxidative stress. The enzyme paraoxonase being antiatherogenic and sensitive to oxidative stress was intriguing in hypertensives. This study was conducted with objectives to determine paraoxonase activity in primary hypertension and to correlate paraoxonase activity to oxidative stress in primary hypertension. In this study there were a total of 60 male subjects which included 30 healthy males as controls and 30 male primary hypertensives without complications of hypertension or any other underlying medical disorder as cases. Our study revealed that serum paraoxonase activity was significantly reduced in hypertensives when compared to controls. Correlation between serum paraoxonase and malondialdehyde with routine biochemistry parameters in both hypertensives and controls was not found to be significant. This study indicated that assessment of serum paraoxonase activity can serve as a predictive factor for atherosclerotic complications in primary hypertensives where oxidative stress is implicated.
Downloads
References
Paul Anand M. API textbook of medicine; Epidemiology of hypertension: 7th edition. Association of physicians of India, Mumbai.
Virdis A, Schiffrin EL. Vascular inflammation: a role in vascular disease in hypertension? Curr Opin Nephrol Hypertens. 2003 Mar; 12(2):181-7.
Rodrigo R, Prat H, Passalacqua W, Araya J, Guichard C, Bächler JP. Relationship between oxidative stress and hypertension. Hypertens Res. 2007 Dec; 30(12):1159-67.
Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al. Humanserum paraoxonase (PON) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation. 2000; 101: 2510–7.
Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans and experimental animals, part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005; 45:142–161.
Draper HH, Hadley M. Methods Enzymol. 1990; 186: 421-431.
Schnackenberg CG. Oxygen radicals in cardiovascular-renal disease. Curr Opin Pharmacol. 2002; 2:121–125.
Ghiadoni, L.; Magagna, A.; Versari, D.; Kardasz, I.; Huang, Y.; Taddei, S.; Salvetti, A. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 41:1281– 1286; 2003.
Lacy, F.; Kailasam, M. T.; O’Connor, D. T.; Schmid-Schonbein, G. W.; Parmer, R. J. Plasma hydrogen peroxide production in human hypertension: role of heredity, gender and ethnicity. Hypertension 36:878– 884; 2000.
Pedro-Botet, J.; Covas, M. I.; Martin, S.; Rubies-Prat, J. Decreased endogenous antioxidant enzymatic status in essential hypertension. J. Hum. Hypertens. 14:343–345; 2000.
Cracowski, J. L.; Baguet, J. P.; Ormezzano, O.; Bessard, J.; Stanke-Labesque, F.; Bessard, G.; Mallion, J. M. Lipid peroxidation is not increased in patients with untreated mild-to-moderate hypertension. Hypertension 41:286– 288; 2003.
Minu Z, Patrignani, P, Gaino, S, Degan, M, Menapace, L, Tommasoli, R, et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 106:2800 – 2805; 2002.
Guillermo T. Sáez, Carmen Tormos, Vicente Giner, Javier Chaves, Jose V. Lozano, et al. Factors Related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension. Am J Hypertension. 2004; 17:809–816.
Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in hypertension: an indicator of renal vascular involvement. Ann Intern Med. 1980; 93:817-21.
Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002; 282:F991-7.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345:861-9.
Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al. Humanserum paraoxonase (PON) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation. 2000; 101: 2510–7.
Uzun H, Karter Y, Aydin S, Curgunlu A, Simsek G, Yucel R, et al. Oxidative stress in white coat hypertnsion; role of paraoxonase. J Hum Hypertens. 2004.
- PDF
Published
How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- An author must submit Copyright form After acceptance of the article.
